{"downloaded": true, "htmlmade": false, "full": {"id": "29669753", "source": "MED", "pmid": "29669753", "pmcid": "PMC5915998", "fullTextIdList": {"fullTextId": "PMC5915998"}, "doi": "10.1182/bloodadvances.2017011916", "title": "Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.", "authorString": "Kumar A, Vardhana S, Moskowitz AJ, Porcu P, Dogan A, Dubovsky JA, Matasar MJ, Zhang Z, Younes A, Horwitz SM.", "authorList": {"author": [{"fullName": "Kumar A", "firstName": "Anita", "lastName": "Kumar", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Memorial Sloan Kettering Cancer Center, New York, NY."}}}, {"fullName": "Vardhana S", "firstName": "Santosha", "lastName": "Vardhana", "initials": "S", "authorId": {"@type": "ORCID", "#text": "0000-0002-3100-1298"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Memorial Sloan Kettering Cancer Center, New York, NY."}}}, {"fullName": "Moskowitz AJ", "firstName": "Alison J", "lastName": "Moskowitz", "initials": "AJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Memorial Sloan Kettering Cancer Center, New York, NY."}}}, {"fullName": "Porcu P", "firstName": "Pierluigi", "lastName": "Porcu", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "The Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, and."}, {"affiliation": "Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH; and."}]}}, {"fullName": "Dogan A", "firstName": "Ahmet", "lastName": "Dogan", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Memorial Sloan Kettering Cancer Center, New York, NY."}}}, {"fullName": "Dubovsky JA", "firstName": "Jason A", "lastName": "Dubovsky", "initials": "JA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA."}}}, {"fullName": "Matasar MJ", "firstName": "Matthew J", "lastName": "Matasar", "initials": "MJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Memorial Sloan Kettering Cancer Center, New York, NY."}}}, {"fullName": "Zhang Z", "firstName": "Zhigang", "lastName": "Zhang", "initials": "Z", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Memorial Sloan Kettering Cancer Center, New York, NY."}}}, {"fullName": "Younes A", "firstName": "Anas", "lastName": "Younes", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Memorial Sloan Kettering Cancer Center, New York, NY."}}}, {"fullName": "Horwitz SM", "firstName": "Steven M", "lastName": "Horwitz", "initials": "SM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Memorial Sloan Kettering Cancer Center, New York, NY."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0002-3100-1298"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "8", "volume": "2", "journalIssueId": "2672065", "dateOfPublication": "2018 Apr", "monthOfPublication": "4", "yearOfPublication": "2018", "printPublicationDate": "2018-04-01", "journal": {"title": "Blood advances", "ISOAbbreviation": "Blood Adv", "medlineAbbreviation": "Blood Adv", "NLMid": "101698425", "ISSN": "2473-9529", "ESSN": "2473-9537"}}, "pubYear": "2018", "pageInfo": "871-876", "abstractText": "Ibrutinib has previously been shown to inhibit Bruton's tyrosine kinase (BTK) and interleukin-2-inducible T-cell kinase (ITK), which mediate B-cell and T-cell receptor signaling, respectively. BTK inhibition with ibrutinib has demonstrated impressive clinical responses in a variety of B-cell malignancies. Whether ibrutinib inhibition of ITK can lead to clinical response in T-cell malignancies is unknown. We hypothesized that ibrutinib-mediated ITK inhibition in T-cell lymphoma would result in decreased signaling through the T-cell receptor pathway and promote antitumor immune response by driving selective cytotoxic Th1 CD4 effector T-cell differentiation. This pilot clinical trial evaluated 2 dose levels of ibrutinib: 560 and 840 mg orally daily. Fourteen patients with relapsed, refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma were enrolled. Both dose levels were safe and well tolerated, and no dose-limiting toxicities were observed. One patient achieved a partial response (overall response rate, 8% [1/13]). ITK occupancy studies demonstrated a mean occupancy of 50% (range, 15%-80%). Higher ITK occupancy of more than 50% correlated with higher serum levels of tumor necrosis factor-\u03b1 and interferon-\u03b3 and favored a Th1 phenotype. Our data suggest that ibrutinib inhibition of ITK has limited clinical activity in T-cell lymphoma. This study is registered at www.clinicaltrials.gov as #NCT02309580.", "affiliation": "Memorial Sloan Kettering Cancer Center, New York, NY.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Clinical Trial", "Research Support, Non-U.S. Gov't", "research-article", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": {"grantId": "P30 CA008748", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Lymphoma, T-Cell", "meshQualifierList": {"meshQualifier": {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Lymphoma, T-Cell, Cutaneous", "meshQualifierList": {"meshQualifier": {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Lymphoma, T-Cell, Peripheral", "meshQualifierList": {"meshQualifier": {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Pyrazoles", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Pyrimidines", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Protein Kinase Inhibitors", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Salvage Therapy", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Pilot Projects"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}]}, "chemicalList": {"chemical": [{"name": "Pyrimidines", "registryNumber": "0"}, {"name": "Pyrazoles", "registryNumber": "0"}, {"name": "Protein Kinase Inhibitors", "registryNumber": "0"}, {"name": "ibrutinib", "registryNumber": "1X70OSD4VX"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/bloodadvances.2017011916"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5915998"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC5915998?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1182/bloodadvances.2017011916"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "5", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-03-08", "dateOfCreation": "2018-04-20", "firstIndexDate": "2018-04-20", "fullTextReceivedDate": "2020-07-14", "dateOfRevision": "2020-12-21", "firstPublicationDate": "2018-04-01"}, "abstract": "Ibrutinib has previously been shown to inhibit Bruton's tyrosine kinase (BTK) and interleukin-2-inducible T-cell kinase (ITK), which mediate B-cell and T-cell receptor signaling, respectively. BTK inhibition with ibrutinib has demonstrated impressive clinical responses in a variety of B-cell malignancies. Whether ibrutinib inhibition of ITK can lead to clinical response in T-cell malignancies is unknown. We hypothesized that ibrutinib-mediated ITK inhibition in T-cell lymphoma would result in decreased signaling through the T-cell receptor pathway and promote antitumor immune response by driving selective cytotoxic Th1 CD4 effector T-cell differentiation. This pilot clinical trial evaluated 2 dose levels of ibrutinib: 560 and 840 mg orally daily. Fourteen patients with relapsed, refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma were enrolled. Both dose levels were safe and well tolerated, and no dose-limiting toxicities were observed. One patient achieved a partial response (overall response rate, 8% [1/13]). ITK occupancy studies demonstrated a mean occupancy of 50% (range, 15%-80%). Higher ITK occupancy of more than 50% correlated with higher serum levels of tumor necrosis factor-\u03b1 and interferon-\u03b3 and favored a Th1 phenotype. Our data suggest that ibrutinib inhibition of ITK has limited clinical activity in T-cell lymphoma. This study is registered at www.clinicaltrials.gov as #NCT02309580.", "journaltitle": "Blood advances", "authorinfo": ["Kumar A", "Vardhana S", "Moskowitz AJ", "Porcu P", "Dogan A", "Dubovsky JA", "Matasar MJ", "Zhang Z", "Younes A", "Horwitz SM"], "title": "Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma."}